title: In vivo administration of antibody to murine IL-5 receptor inhibits eosinophilia of IL-5 transgenic mice.
abstract: We investigated the in vivo role of interleukin 5 (IL-5) and its receptor (IL-5R) in eosinophil growth and differentiation. When mice were administered IL-5 i.p., an increase in the number of eosinophils was observed within 5 days in peripheral blood and the peritoneal cavity. Hypereosinophilia was observed in IL-5 transgenic mice who displayed constitutive production of IL-5. A binding assay with 35S-labeled IL-5 revealed the presence of two classes of IL-5 binding sites (low and high affinity) on the surface of eosinophils. IL-5Rs on eosinophils were recognized using mAbs against murine IL-5R. When the IL-5 transgenic mice were passively administered with anti-murine IL-5R mAbs, the number of recognizable eosinophils in peripheral blood dropped within 5 days to normal levels. The antibody treatment also prevented the increase in the number of eosinophils in IL-5-injected mice. The inhibition of the above experimental eosinophilia was also observed by the passive administration of anti-IL-5 mAb. The results of the in vivo experiments clearly demonstrate that IL-5 plays an essential role in in vivo eosinophilopoiesis and may be acting on eosinophils or their precursors directly through IL-5Rs, resulting in preferential growth of this lineage of hematopoietic cells. It can also be stressed that IL-5 regulates a specific lineage of hematopoietic cells (eosinophils).
authors.affiliation: Department of Biology, University Medical School, Kumamoto, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hitoshi
authors.forename: N
authors.initials: N
authors.lastname: Yamaguchi
authors.forename: M
authors.initials: M
authors.lastname: Korenaga
authors.forename: S
authors.initials: S
authors.lastname: Mita
authors.forename: A
authors.initials: A
authors.lastname: Tominaga
authors.forename: K
authors.initials: K
authors.lastname: Takatsu
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D001665:Binding Sites / Q000276:immunology; D002452:Cell Count; D004802:Eosinophilia / Q000276:immunology / Q000517:prevention & control*; D004804:Eosinophils / Q000378:metabolism; D005260:Female; D007114:Immunization; D015848:Interleukin-5 / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D011971:Receptors, Immunologic / Q000276:immunology* / Q000378:metabolism; D018123:Receptors, Interleukin; D053649:Receptors, Interleukin-5
chemical_list: D000911:Antibodies, Monoclonal; D015848:Interleukin-5; D011971:Receptors, Immunologic; D018123:Receptors, Interleukin; D053649:Receptors, Interleukin-5